Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/30325
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12502]
Metadatos
Mostrar el registro completo del ítem
ENDOGENOUS ANTICANCER MECHANISM: DIFFERENTIATION
Werneck, Miriam Bianchi Frontin | Fecha del documento:
2012
Afiliación
Instituo Nacional de Câncer. Programa de Biologia Celular. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Resumen en ingles
It has been recently shown that within
heterogeneous tumor masses a small population of less
differentiated transformed cells has the ability to self-renew
and regenerate the bulk of the tumor. Their similarities with
normal stem cells in terms of gene expression patterns,
proliferative capacity and surface markers rendered them
the name of cancer stem-like cells (CSC), and these are
thought to be the tumor initiating cells (TIC). Their limited
susceptibility to classical anti-tumor therapy help explain
the high incidence of cancer-treatment relapses observed in
selected malignancies. Much effort is being directed
towards the understanding of factors that maintain CSC
survival and their self-renewal capacity, with the goal that
these same signaling pathways can be harnessed for
treatments that aim at inducing CSC differentiation. This
review will discuss the CSC theory, its implications,
potential signaling pathways responsible for maintaining
their undifferentiated and pluripotent states, and new
venues being explored to target these cells in modern
cancer therapy.
Compartir